Terms: = Prostate cancer AND BCL2, Bcl-2, 596, ENSG00000171791 AND Treatment
1013 results:
1. Integrated aerobic exercise with LDE-docetaxel treatment: a novel approach to combat prostate cancer progression.
Veras ASC; Batista VRG; Correia RR; de Almeida Tavares ME; Rubira RJG; Tavares ER; Giometti IC; Maranhão RC; Teixeira GR
Sci Rep; 2024 Apr; 14(1):9626. PubMed ID: 38671015
[TBL] [Abstract] [Full Text] [Related]
2. HPLC-ESI/MS-MS metabolic profiling of white pitaya fruit and cytotoxic potential against cervical cancer: Comparative studies, synergistic effects, and molecular mechanistic approaches.
El-Nashar HAS; Al-Azzawi MA; Al-Kazzaz HH; Alghanimi YK; Kocaebli SM; Alhmammi M; Asad A; Salam T; El-Shazly M; Ali MAM
J Pharm Biomed Anal; 2024 Jul; 244():116121. PubMed ID: 38581932
[TBL] [Abstract] [Full Text] [Related]
3.
Kim SY; Park JE; Lee HJ; Sim DY; Ahn CH; Park SY; Shim BS; Kim B; Lee DY; Kim SH
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474045
[TBL] [Abstract] [Full Text] [Related]
4. Optimizing combination therapy in prostate cancer: mechanistic insights into the synergistic effects of Paclitaxel and Sulforaphane-induced apoptosis.
Habib TN; Altonsy MO; Ghanem SA; Salama MS; Hosny MA
BMC Mol Cell Biol; 2024 Mar; 25(1):5. PubMed ID: 38438917
[TBL] [Abstract] [Full Text] [Related]
5. Combination of navitoclax (bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway.
Asdemir A; Özgür A
Med Oncol; 2024 Mar; 41(4):83. PubMed ID: 38436810
[TBL] [Abstract] [Full Text] [Related]
6. Investigation of in-vitro Anti-cancer and Apoptotic Potential of Garlic-Derived Nanovesicles against prostate and Cervical cancer Cell Lines.
Sharma V; Sinha ES; Singh J
Asian Pac J Cancer Prev; 2024 Feb; 25(2):575-585. PubMed ID: 38415544
[TBL] [Abstract] [Full Text] [Related]
7. Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and prostate cancer Detection.
Morote J; Picola N; Muñoz-Rodriguez J; Paesano N; Ruiz-Plazas X; Muñoz-Rivero MV; Celma A; Manuel GG; Miró B; Servian P; Abascal JM
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397430
[TBL] [Abstract] [Full Text] [Related]
8. Pretargeted radiotherapy and synergistic treatment of metastatic, castration-resistant prostate cancer using cross-linked, PSMA-targeted lipoic acid nanoparticles.
Dai L; Zhang X; Zhou S; Li J; Pan L; Liao C; Wang Z; Chen Y; Shen G; Li L; Tian R; Sun H; Liu Z; Zhang S; Wu H
J Mater Chem B; 2024 Feb; 12(9):2324-2333. PubMed ID: 38324337
[TBL] [Abstract] [Full Text] [Related]
9. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract] [Full Text] [Related]
10. Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells.
Ghorbani R; Gharbavi M; Sharafi A; Rismani E; Rezaeejam H; Mortazavi Y; Johari B
Oncol Res; 2023; 32(1):101-125. PubMed ID: 38188680
[TBL] [Abstract] [Full Text] [Related]
11. Quality by design fostered fabrication of cabazitaxel loaded pH-responsive Improved nanotherapeutics against prostate cancer.
Shah S; Famta P; Kumar R; Sharma A; Vambhurkar G; Pandey G; Singh G; Kumar P; Mehra A; Mourya A; Srinivasarao DA; Shinde A; Prasad SB; Khatri DK; Madan J; Srivastava S
Colloids Surf B Biointerfaces; 2024 Feb; 234():113732. PubMed ID: 38181691
[TBL] [Abstract] [Full Text] [Related]
12. Tailored horseshoe-shaped nicotinonitrile scaffold as dual promising c-Met and Pim-1 inhibitors: Design, synthesis, SAR and in silico study.
Mohamady S; Khalil AF; Naguib BH; Nafie MS; Tawfik HO; Shaldam MA
Bioorg Chem; 2024 Feb; 143():106988. PubMed ID: 37995644
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
14. Targeting androgen receptor (AR) with a synthetic peptide increases apoptosis in triple negative breast cancer and AR-expressing prostate cancer cell lines.
Jamshidi M; Keshavarzi F; Amini S; Laher I; Gheysarzadeh A; Davari K
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1922. PubMed ID: 37903548
[TBL] [Abstract] [Full Text] [Related]
15. Aridanin and oleanane-3- O-β-D-glucoside-2'-acetamide obtained from Tetrapleura tetraptera (Schumach. & Thonn) Taub. (Fabaceae) induces potent apoptotic activity in human prostate cancer cells.
Kamdem MHK; Zingue S; Grein T; Maxeiner S; Rutz J; Mmutlane EM; Njamen D; Blaheta RA; Ndinteh DT
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117298. PubMed ID: 37866463
[TBL] [Abstract] [Full Text] [Related]
16. Dual Strategy with Adipose-Derived Stem Cells and l-arginine Recovered Cavernosal Functions in a Rat Model of Radical prostatectomy.
Yilmaz-Oral D; Sezen SF; Turkcan D; Asker H; Kaya-Sezginer E; Kirlangic OF; Kopru CZ; Elci MP; Ozen FZ; Korkusuz P; Oren S; Oztekin CV; Ates I; Gur S
Stem Cells Dev; 2024 Jan; 33(1-2):43-53. PubMed ID: 37847152
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Investigation of the Antitumor Effects of Monoamine Oxidase Inhibitors in Breast cancer Cells.
Alkhawaldeh A; Bardaweel S
Biomed Res Int; 2023; 2023():2592691. PubMed ID: 37841082
[TBL] [Abstract] [Full Text] [Related]
18. Targeting the Metabolic Enzyme PGAM2 Overcomes Enzalutamide Resistance in Castration-Resistant prostate cancer by Inhibiting bcl2 Signaling.
Li Z; Ning K; Zhao D; Zhou Z; Zhao J; Long X; Yang Z; Chen D; Cai X; Hong L; Zhang L; Zhou F; Wang J; Li Y
Cancer Res; 2023 Nov; 83(22):3753-3766. PubMed ID: 37676279
[TBL] [Abstract] [Full Text] [Related]
19. Combined Dextran-Graft-Polyacrylamide/Zinc Oxide Nanocarrier for Effective Anticancer Therapy in vitro.
Chumachenko V; Virych P; Nie G; Virych P; Yeshchenko O; Khort P; Tkachenko A; Prokopiuk V; Lukianova N; Zadvornyi T; Rawiso M; Ding L; Kutsevol N
Int J Nanomedicine; 2023; 18():4821-4838. PubMed ID: 37662686
[TBL] [Abstract] [Full Text] [Related]
20. Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced prostate cancer.
Neeb A; Figueiredo I; Gurel B; Nava Rodrigues D; Rekowski J; Riisnaes R; Ferreira A; Miranda S; Crespo M; Westaby D; de Los Dolores Fenor de La Maza M; Guo C; Carmichael J; Grochot R; Tunariu N; Cato ACB; Plymate SR; de Bono JS; Sharp A
Lab Invest; 2023 Nov; 103(11):100245. PubMed ID: 37652207
[TBL] [Abstract] [Full Text] [Related]
[Next]
